Capricor Positive Type-B Meeting with FDA for CAP-1002 Program for Duchenne

 --FDA Grants Pre-BLA Meeting Request and Rolling BLA Submission after Review of HOPE-2 and HOPE-2 OLE 3-Year Results--

https://www.biospace.com/article/releases/capricor-therapeutics-announces-positive-type-b-meeting-with-fda-for-cap-1002-program-for-duchenne-muscular-dystrophy-with-an-aim-to-expedite-bla-pathway/